Recruiting Diffuse Large B-Cell Lymphoma Studies in Lexington
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment ...
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that ...
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lena...
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standa...
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitam...
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBC...
About Diffuse Large B-Cell Lymphoma Clinical Trials in Lexington
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for about 30% of cases. It is an aggressive lymphoma that grows rapidly. Treatment usually involves chemoimmunotherapy, with CAR-T cell therapy for relapsed cases.
There are currently 6 diffuse large b-cell lymphoma clinical trials recruiting participants in Lexington, KENTUCKY. These studies are seeking a combined 2,470 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Genmab, Hoffmann-La Roche and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Diffuse Large B-Cell Lymphoma Clinical Trials in Lexington — FAQ
Are there diffuse large b-cell lymphoma clinical trials in Lexington?
Yes, there are 6 diffuse large b-cell lymphoma clinical trials currently recruiting in Lexington, KENTUCKY. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Lexington?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Lexington research site will contact you about next steps.
Are clinical trials in Lexington free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Lexington studies also compensate for your time and travel.
What diffuse large b-cell lymphoma treatments are being tested?
The 6 active trials in Lexington are testing new therapies including novel drugs, biologics, and treatment approaches for diffuse large b-cell lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov